Działanie probiotyków na organizm człowieka. Cz. II. Zastosowanie probiotyków w leczeniu i profilaktyce chorób

1. Strus M, Kukla G, Rurańska-Smutnicka D i wsp. Właściwości powierzchniowe bakterii z rodzaju Lactobacillus. II Adherencja do lini komórkowych. Med Dośw Mikrobiol 2001; 53:253-8. 2. Tissier H. Traitement des infectious intestinalis par la methode de la flore bacterienne de l´intestin. CR Soc Biol 1906; 60:359-61. 3. Romonad MD, Haddou Z, Mielcarek C i wsp. Bifidobacterium and human health: regulatory effect of indigenous bifidobacteria on Escherichia coli intestinal colonization. Anaerobe 1997; 3:131-6. 4. Gonzalez SN, Appella MC, Romero NC i wsp. Inhibition of enteropathogenes by lactobacilli strains used in fermentem milk. J Food Protect 1993; 56:773-6. 5. Drago L, Gismondo MR, Lombardi A, i wsp. Inhibition of in vitro growth of enteropathogenes by new Lactobacillus isolates of human intestinal origin. FEMS Microbiol Lett 1997; 153:455-63. 6. Hudault S, Lievin V, Bernet-Camard MF i wsp. Antagonistic activity exerted in vitro and in vivo by Lactobacillus casei (strain GG) against Salmonella typhimurium C 5 infection. Appl Environ Microbiol 1997; 63:513-8. 7. Suzuki T, Itoh K, Kaneko T, Suzuki H. Inhibition of bacteria translocation from the gastrointestinal tract of mice by oral administration of a culture condensate of Bifidobacterium longum.J Vet Med Sci 1997; 59(8):665-9. 8. Chauviere G, Coconnier MH, Kernei SS i wsp. Adhesion of human Lactobacillus acidophilus strain LB to human erytrocyte-like Caco-2. J Gen Microbiol 1992; 138:1689-1696. 9. Bernet MF, Brassat D, Neeser JR i wsp. Lactobacillus acidophilus LA1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994; 35:483-9. 10. Gopal PK, Prasad J, Smart J i wsp. In vitro adherence properties of Lactobacilli rhamnosus DR 20 and Bifidobacterium lactis DR 10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. Int J Food Microbiol 2001; 67:207-16. 11. Connier MH, Bernet MF, Kerneis S i wsp. Inhibition of adhesion of enteroinvasive pathogens to human intestinal Caco-2 cells by Lactobacillus acidophilus strain LB decreases bacterial invasion. FEMS Microbiol Lett 1993; 110:299-305. 12. Lin CK, Tsai HC, Lin PP i wsp. Lactobacillus acidophilus LA P5 able to inhibit the Salmonella choleresuis invasion to the human Caco-2 epithelial cell. Anaerobe 2008; 14:252-5. 13. Bernet MF, Brassart D, Neeser JR i wsp. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. Appl Environ Microbiol 1993; 59:4121-8. 14. He F, Ouwenhan AC, Hashimoto H i wsp. Adhesion of Bifidobacterium spp. to human intestinal mucous. Microbiol Immunol 2001; 45:259-61. 15. Perez PF, Minnaard Y, Disalvo EA i wsp. Surface properties of bifidobacterial strains of human origin. Appl Environ Microbiol 1998; 64(1): 21-6. 16. Ramond MB, Colavizza M, Mullie C i wsp. Does the intestinal bifidobacterial colonization affect bacterial translocation? Anaerobe 2008; 14:43-8. 17. Jeppsson B, Mangell P, Adawi D i wsp. Bacterial translocation: impact of probiotics. Scand J Nutr 2004; 48(1):37-41. 18. Mattar AF, Drongowski RA, Coran AG i wsp. Effect of probiotic on enterocyte bacterial translocation in vitro. Pediatr Surg Int 2001; 17:265-8. 19. Johansson ML, Molin G, Jeppsson B. Administration of different Lactobacillus strains in fermentem oat meat soup: in vitro colonization of human intestine mucosa and effect on the indigenous flora. Appl Environ Microbiol. 1993; 59:15-20. 20. Oksanen PJ, Salminen S, Saxelin M i wsp. Prevention of travellers´ diarrhoeae by Lactobacillus GG. Ann Med J 1990; 22:53-6. 21. Hilton E, Kolakowski P, Singer C i wsp. Efficacy of Lactobacillus GG as a diarrheal prevention in travelers. J Travel Med 1997; 4:41-3. 22. Scarpignato C, Rampal P. Prevention and treatment of traveler´s diarrhea: a clinical, pharmacological approach. Chemotherapy 1995; 41(Suppl. 1):48-81. 23. Mc Farland L. Meta-analysis of probiotics for the prevention of traveler´s diarrhea. Travel Med Infec Dis 2007; 5:97-105. 24. Corthier G, Dubos F, Raibaund P. Modulation of cytotoxin production by Clostridium difficile in the intestinal tract of gnotobiotic mice inoculated with various human intestinal bacteria. Appl Environ Microbiol 1985; 49:250-2. 25. Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987; 2:1519-20. 26. Briller JA, Katz AJ, Flores AD i wsp. Treatment of reccurent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995; 21:224-6. 27. Szajewska H, Mrukowicz J. Metaanalysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2005; 22:365-72. 28. Gaon D, Garcia H, Winter L i wsp. Effect of Lactobacillus strains and Saccharomyces boulardii on persistant diarrhea in children. Medicina 2003; 63:293-8. 29. Wells CL, Van de Weterlo EMA, Jechorek RP i wsp. Bacteroides fragilis enterotoxin modulates epithelial permeability and internalization by HT-29 enterocytes. Gastroenterology 1996; 110:1429-37. 30. Sack RB, Albert MJ, Alam K i wsp. Isolation of enterotoxicogenic Bacteroides fragilis from Bangladeshi children with diarrhea: a controlled study. J Clin Microbiol 1994; 32:960-3. 31. Szoke I, Dosa E, Nagy E. Enterotoxigenic Bacteroides fragilis in Hungary. Anaerobe 1997; 3(4):87-9. 32. Meyers LL, Shoop DS, Stackhouse LL i wsp. Isolation of enterotoxigenic Bacteroides fragilis from humans with diarrhea. J Clin Microbiol 1987; 25:2330-3. 33. Saavedra JM, Bauman NA, Oung I i wsp. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infantis in hospital for prevention of diarrhea and shedding of rotavirus. Lancet 1994; 344:1046-9. 34. Isolauri E. Probiotics in human disease. Am J Clin Nutr 2001; 73(suppl):1142S-6S. 35. Haschke F, Wang W, Ping G i wsp. Clinical trials prove the safety and efficacy of the probiotics strain Bifidobacterium Bb 12 in follow-up formula and growing-up milks. Monatsschr Kinderheilkd 1998;(supl 1)146:S26-S30. 36. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infection diarrhea in infants and children: a systematic review of publisher randomized double-blind, placebo-controlled trias. J Pediatr Gastroenterol Nutr 2001; 33(Suppl 2):17-25. 37. Duffy LC, Zielezny MA, Riepenhoff-Talty M. Effectivenes of Bifidobacterium in mediating the clinical course of Marine rotavirus diarrhea. Pediatr Res 1994; 36:590-5. 38. Yasni H, Kiyoshima J, Ushihama H. Passive protection against rotavirus-induced diarrhea of mouse pups born to and nursed by dams fed Bifidobacterium breve YIT 4064. J Infect Dis 1995; 172:403-9. 39. Oberhelman RA, Gilman RH, Sheen P i wsp. A placebo-controlled trial of Lactobacillus GG to present diarrhea in undernourished Peruvian children. J Pediatr 1999; 134:15-20. 40. Born P, Learsch C, Zimmerhackl B i wsp. The Saccharomyces boulardii therapy of HIV associated diarrhea (letter). Dtsch Med Wochenschr 1993; 118:765-6. 41.Saint-Marea T, Rosello-Prats L, Touraine JL. Efficacite de Saccharomyces boulardii dans le traitment du SIDA. Ann Med. Int 1991; 142:64-5. 42. Coconnier MH, Lievin V, Hemery E i wsp. Antagonistic activity against Helicobacter infection in vitro and in vivo by human Lactobacillus acidophilus strain LA. Appl Environ Microbiol 1998; 64:4573-80 43. Michetti P, Dorta G, Brassard D i wsp. Lactobacillus acidophilus supernatant as an adjuvant in the therapy of H. pylori in humans. Gastroenterology 1995; 108:A166. 44. Cazzato IA, Candelli M, Nista EG i wsp. Role of probiotics in Helicobacter pylori infection. Scand J Nutr 2004; 48(1):26-31. 45. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000; 130(2S Suppl):396-402S. 46. Reid G, Bruce AW, Cook RL. Examination of strains of Lactobacilli for properties that may influence bacterial interference in the urinary tract. J Urol 1987; 138:330-5. 47. Conway PL, Gorbach SL, Goldin BR. Survival of lactic acid bacteria in the human stomach and adversion to intestinal cells. J Dairy Sci 1987; 70:1-12. 48. Lorca GL, Wadstrom T, Valdez GF i wsp. Lactobacillus acidophilus autolysin inhibit Helicobacter pylori in vitro. Curr Microbiol 2001; 42:39-44. 49. Kabir AM, Aiba Y, Takagi A i wsp. Prevention of Helicobacter pylori infection by Lactobacilli in a gnotobiotic Marine model. Gut 1997; 41:49-55. 50. Aiba Y, Suzuki N, Kabir AM i wsp. Lactic acid-mediated suppresion of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic Marine model. Am J Gastroenterol 1998; 93:2097-101. 51. Mukai T, Asasaka T, Sato E i wsp. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri.FEMS Immunol Med Microbiol 2002; 32:105-10. 52. Kruis W, Schultz E, Fixa P i wsp. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11:853-8. 53. Gionchetti P, Rizzello F, Venturi A i wsp. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchiris. A double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305-9. 54. Ruseler-Van Embolen JGH, Hazenberg MP, Van Lieshout LMC i wsp. Instability of the pouch flora: causa of pouchitis? Microecol Ther 1995; 23:81-88. 55. Guslandi M, Giollo P, Testonii PA. Saccharomyces boulardii in maintenance treatment of Crohn´s disease. Dig Dis Scri 2000; 45:1462-4. 56. Gustlandii M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15:697-8. 57. Madsen KL, Doye JS, Jewell D i wsp. Lactobacillus species prevent colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116:1107-14. 58. Gan BS, Kim J, Reid G i wsp. Lactobacillus fermentum RC-14 inhibits Staphylococcus aureus infection of surgical implants in rats. J Infect Dis 2002; 185:1369-72. 59. Rayes N, Hansen S, Seehofer D i wsp. Early enteral supply of fiber and lactobacilli versus conventional nutrition: a controlled trial in patients with major abdominal surgery. Nutrition 2002; 18:609-15. 60. Reid GA, Bruce W, Taylor M. Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. Microccol Ther 1995; 23:32-45. 61. Reid GA, Bruce W, Fraser N i wsp. Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol 2001; 30:49-52. 62. Reid G, Lam D, Bruce AW i wsp. Adhesion of lactobacilli to urinary catheters and diapers: effect of surface properties. J Biomed Mater Res 1994; 28:731-4(3). 63. Reid G, Bruce AW, Smeianov V. The role of lactobacilli in preventing urogenital and intestinal infection. Int Dairy J 1998; 8:555-62. 64. Hilton E, Isenberg HO, Alperstein P i wsp. Ingestion of jogurt containing Lactobacillus acidophilus as prophylaxis for candida vaginitis. Ann Intern Med 1992; 116: 353-7. 65. Isolauri E, Arvola T, Sutas Y i wsp. Probiotics in the management of topic eczema. Clin Exp Allergy 2000; 30:1604-10(1). 66. Kalliomaki M, Salminen S, Avilommi H i wsp. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001: 357:1076-9. 67. Majamaa H, Isolauri E. Evaluation of the gut mucosal barier: evidence for increased antygen transfer in children with atopic eczema. J Allergy Clin Immunol 1996; 97:985-90. 68. Salminen S, Isolauri E, Salminen E. Probiotics and stabilization of the gut mucosal barier. Asia Pac J Clin Nutr 1996; 5:53-6. 69. Kim HS, Gilliland SE. Lactobacillus acidophilus as a dietary adjunct for milk to acid lactose digestion in humans. J Diary Sci 1983; 66:959-66. 70. Gobbetti M, Rizzello CR, Di Cagno R i wsp. Souroudh lactobacilli and celiac disease. Food Microbiol 2007; 24:187-96. 71. Goldin BR. Intestinal microflora: metabolism of drugs and carcinogens. Ann Med J 1990; 22:43-8. 72. Goldin BR, Swenson L, Dowyer J i wsp. Effect of diet and Lactobacillus acidophilus supplements on human fecal bacterial enzymes. J Natl Cancer Inst 1980; 64:255-61. 73. Marteau P, Pochart P, Flourie B i wsp. Effect of chronic ingestin of a fermentem dairy product containing Lactobacillus acidophilus and Bifidobacterium bifidum on metabolic activities of the colonic flora in humans. Am J Clin Nutr 1990; 52:685-8. 74. Orrhange K, Sillvestrom E, Gustafsson JA i wsp. Binding of mutagenic heterocyclic amines by intestinal and lactic acid bacteria. Mutat Res 1994; 311:239-48. 75. Hayatsu H, Hayatsu T. Suppressing effects of Lactobacillus casei administration on the urinary mutagenicity arising from ingestion of fried ground beef in the human. Cancer Lett 1993; 73:173-9. 76. Liebeck A, Nord CE, Gustaffson JA i wsp. Lactobacilli,anticarcinogenic activities and human intestinal microflora. Eur J Cancer Prev 1992; 1:341-53. 77. Goldin BR, Gorbach SL. Effect of Lactobacillus acidophilus dietary supplements on 1,2-dimethylhydrazine dihydrochloride - induced intestinal cancer in cats. J Natl Cancer Inst 1980; 64:263-5. 78. Reddy BS, Rivenson A. Inhibitory effect of Bifidobacterium longum on colon, mammary and liver carcinogenesis induced by 2-amino-3-methyl-imidazol/4,5-t/quinoline, food mutagen. Cancer Res 1993; 53:3914-8. 79. Gill HS. Stimulation of the immune system by lactic cultures. Int Dairy J 1998; 8:535-44. 80. Schiffin EJ, Brassart D, Servin AL i wsp. Immune modulation of blood leukocytes in humans by lactic acid bacteria: criteria for strain selection. Am J Cli Nutr 1977; 66:515S-20S. 81. Fukushima Y, Kawata Y, Hara H i wsp. Effect of a probiotic formula on intestinal immunoglobulin A production in health children. Int J Food Microbiol 1998; 42:39-44. 82. Malin M, Soumalainen H, Saxelin M i wsp. Promotion of IgA immune response in patients with Crohn´s disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996; 40:137-45. 83. Marteau P, Rambaud JC. Potential of using lactic acid bacteria for therapy and immunomodulation in man. FEMS Microbiol Rev 1993; 12:207-20. 84. Naruszewicz M, Johansson ML, Zapolska-Downar D i wsp. Effect of Lactobacilius plantarum 299v on cardiovascular risk factors in smokers. Czynniki Ryzyka 2001; 3-4:19(abstr.). 85. Agerholm-Larsen L, Bell ML, Grunwald GK i wsp. The effect of probiotic milk product on plasma cholesterol: meta-analysis of short-term intervencion studies. Eur J Clin Nutr 2000: 54:856-60. 86. Harrison VG, Peat G. Serum cholesterol and bowel flora in the newborn. Am J Clin Nutr 1975; 28:1351-5. 87. Mann GV. A factor in jogurt which lowers cholesterolemia in man. Atherosclerosis 1977; 26:335-40. 88. Hepner G, Fried R, Icor S i wsp. Hypocholesterolemic effect of jogurt and milk. Am J Clin Nutr 1979; 32:19-24. 89. Fukushima M, Nakano M. The effect of a probiotic on faecal and liver classes in rats. Br J Nutr 1995; 73:701-10. 90. Hata Y, Yamamoto M, Ohni M i wsp. A placebo controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr 1996; 64: 767-71.